Garmin has announced its new product in the crowded wrist-worn devices arena --- its 'Vivosmart' activity tracker.
The Vivosmart activity tracker from Garmin will be priced at $170; and will be exclusively available from this November onwards at Best Buy. The fitness tracker will come with an optional heart rate monitor which will separately cost $30.
Boasting a minimalistic design, though with subtle stylishness, the Garmin Vivosmart fitness-tracking device is a black band worn which is around the wrist. The water-proof tracker has a curved gesture-control smart display which can be turned on by a movement of the wearer's arm or a touch on the device.
The Vivosmart activity tracker enables the wearers to control music, and keep track of their steps, distance and calories burnt --- all from their wrists. In addition, the device also has the capability to remotely control the Garmin VIRB action camera.
If the users have been sitting for too long, the Vivosmart tracker has a move bar to nudge them into action with the help of vibration alerts.
Though the Vivosmart fitness tracker - which will be available in five color options - primarily works with the Garmin Connect app, it can also integrate with RunKeeper and other third-party apps.
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
In an announcement made on Friday, tech giant Google has revealed that the users of the Inbox by...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
In an announcement made via a blog post on Thursday,...
In a blog post published on Wednesday, Twitter-owned...
A draft New York legislation proposes the use of a...
Taiwanese device manufacturer HTC has officially...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).